6 453

Cited 96 times in

Frequent inactivation of SPARC by promoter hypermethylation in colon cancers

DC FieldValueLanguage
dc.contributor.author이환석-
dc.contributor.author강현주-
dc.contributor.author고귀혜-
dc.contributor.author김남규-
dc.contributor.author김호근-
dc.date.accessioned2014-12-21T16:40:34Z-
dc.date.available2014-12-21T16:40:34Z-
dc.date.issued2007-
dc.identifier.issn0020-7136-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/96138-
dc.description.abstractEpigenetic modification of gene expression plays an important role in the development of human cancers. The inactivation of SPARC through CpG island methylation was studied in colon cancers using oligonucleotide microarray analysis and methylation specific PCR (MSP). Gene expression of 7 colon cancer cell lines was evaluated before and after treatment with the demethylating agent 5-aza-2′-deoxycytidine (5Aza-dC) by oligonucleotide microarray analysis. Expression of SPARC was further examined in colon cancer cell lines and primary colorectal cancers, and the methylation status of the SPARC promoter was determined by MSP. SPARC expression was undetectable in 5 of 7 (71%) colorectal cancer cell lines. Induction of SPARC was demonstrated after treatment with the demethylating agent 5Aza-dC in 5 of the 7 cell lines. We examined the methylation status of the CpG island of SPARC in 7 colon cancer cell lines and in 20 test set of colon cancer tissues. MSP demonstrated hypermethylation of the CpG island of SPARC in 6 of 7 cell lines and in all 20 primary colon cancers, when compared with only 3 of 20 normal colon mucosa. Immunohistochemical analysis showed that SPARC expression was downregulated or absent in 17 of 20 colon cancers. A survival analysis of 292 validation set of colorectal carcinoma patients revealed a poorer prognosis for patients lacking SPARC expression than for patients with normal SPARC expression (56.79% vs. 75.83% 5-year survival rate, p = 0.0014). The results indicate that epigenetic gene silencing of SPARC is frequent in colon cancers, and that inactivation of SPARC is related to rapid progression of colon cancers.-
dc.description.statementOfResponsibilityopen-
dc.format.extent567~575-
dc.relation.isPartOfINTERNATIONAL JOURNAL OF CANCER-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAzacitidine/analogs & derivatives-
dc.subject.MESHAzacitidine/pharmacology-
dc.subject.MESHCell Line, Tumor-
dc.subject.MESHColonic Neoplasms/genetics*-
dc.subject.MESHCpG Islands-
dc.subject.MESHDNA Methylation*-
dc.subject.MESHDNA, Neoplasm-
dc.subject.MESHDecitabine-
dc.subject.MESHGene Expression Regulation, Neoplastic-
dc.subject.MESHHumans-
dc.subject.MESHOligonucleotide Array Sequence Analysis-
dc.subject.MESHOsteonectin/genetics*-
dc.subject.MESHPrognosis-
dc.subject.MESHPromoter Regions, Genetic*-
dc.subject.MESHSurvival Analysis-
dc.titleFrequent inactivation of SPARC by promoter hypermethylation in colon cancers-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Clinical Genetics (임상유전학)-
dc.contributor.googleauthorEungi Yang-
dc.contributor.googleauthorHyun Ju Kang-
dc.contributor.googleauthorHoguen Kim-
dc.contributor.googleauthorNam Kyu Kim-
dc.contributor.googleauthorHwanseok Rhee-
dc.contributor.googleauthorKwi Hye Koh-
dc.identifier.doi10.1002/ijc.22706-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA03334-
dc.contributor.localIdA00111-
dc.contributor.localIdA00353-
dc.contributor.localIdA01183-
dc.contributor.localIdA00092-
dc.relation.journalcodeJ01092-
dc.identifier.eissn1097-0215-
dc.identifier.pmid17397030-
dc.identifier.urlhttp://onlinelibrary.wiley.com/doi/10.1002/ijc.22706/abstract-
dc.contributor.alternativeNameRhee, Hwan Seok-
dc.contributor.alternativeNameKang, Hyun Ju-
dc.contributor.alternativeNameKoh, Kwi Hye-
dc.contributor.alternativeNameKim, Nam Kyu-
dc.contributor.alternativeNameKim, Ho Keun-
dc.contributor.affiliatedAuthorRhee, Hwan Seok-
dc.contributor.affiliatedAuthorKoh, Kwi Hye-
dc.contributor.affiliatedAuthorKim, Nam Kyu-
dc.contributor.affiliatedAuthorKim, Ho Keun-
dc.contributor.affiliatedAuthorKang, Hyun Ju-
dc.rights.accessRightsnot free-
dc.citation.volume121-
dc.citation.number3-
dc.citation.startPage567-
dc.citation.endPage575-
dc.identifier.bibliographicCitationINTERNATIONAL JOURNAL OF CANCER, Vol.121(3) : 567-575, 2007-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Clinical Genetics (임상유전학과) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.